TEVA (TEVJF) Form 144 Files Sale of 95,000 ADS via Piper Sandler
Rhea-AI Filing Summary
Form 144 notice for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF): The filer notifies a proposed sale of 95,000 American Depositary Shares through Piper Sandler & Co. (Greenwich, CT) with an approximate aggregate market value of $1,889,550.00. The securities outstanding figure listed is 1,147,150,917. The proposed approximate sale date is 09/12/2025. The shares were acquired on 05/09/2018 and the date of payment is recorded as 05/09/2018. The filing reports "Nothing to Report" for securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
Positive
- Complete Rule 144 disclosure with broker, quantity, aggregate value, acquisition date, and planned sale date
- No securities sold in the past three months, as explicitly reported
- Seller's representation included that no undisclosed material adverse information is known
Negative
- None.
Insights
TL;DR: Routine Rule 144 sale notice disclosing 95,000 ADS to be sold via Piper Sandler; limited near-term market impact expected from this size.
The filing supplies standard Rule 144 disclosure: class, broker, quantity, aggregate value, outstanding shares, acquisition date, and planned sale date. The quantity (95,000 ADS) and aggregate value (~$1.89M) are explicit and represent a small fraction of the reported outstanding ADS, implying limited direct dilution or market pressure from this single filing alone. No recent sales in the prior three months are reported. This is a compliance-focused disclosure rather than an operational or financial development.
TL;DR: Filing appears procedurally complete; includes seller representation about absence of undisclosed material adverse information.
The notice includes required statements regarding acquisition details and seller certification about material information, and names a broker-dealer executing the sale. Acquisition and payment dates are provided, and remarks emphasize criminal penalties for misstatements. There are no indications of plan adoption dates or contingent payment terms disclosed. From a compliance perspective, the document meets typical Rule 144 reporting requirements but contains no new operational or risk disclosures about the issuer.